Mohammad, Khalid S.Guise, Theresa A.Manzano García, MiguelVallet Regí, María Dulce Nombre2023-06-172023-06-172017-01-272377-090210.15436/2377-0902.17.1188https://hdl.handle.net/20.500.14352/17671RESEARCHER ID K-3719-2014(Miguel Manzano García) ORCID 0000-0001-6238-6111(Miguel Manzano García) RESEARCHER ID M-3378-2014 (María Vallet Regí) ORCID 0000-0002-6104-4889 (María Vallet Regí)Cancer-associated muscle dysfunction represents a deadly clinical problem, with ca. 80% mortality together with an increased toxicity from cancer treatment.. The normal bone remodeling might be disrupted by tumor cells that metastasize to bone in certain stages of cancer, which results in increased morbidity including muscle weakness. The reason for that muscle weakness might be attributed to the reduction on muscle mass or the reduction of muscle function. In fact, it has been demonstrated that in advanced cancers, it is probably caused by a combination of reductions, quantity and quality of muscle. This review focuses on the mechanisms that bone metastases promote skeletal muscle weakness.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttp://www.ommegaonline.org/open access54666Química inorgánica (Farmacia)